Zanzalintinib information

Zanzalintinib
Clinical data
Other names	XL092
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-N′-(4-Fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide;
CAS Number	2367004-54-2;
PubChem CID	139350422;
ChemSpider	114641993;
UNII	KC2JC2ZA04;
Chemical and physical data
Formula	C29H25FN4O5
Molar mass	528.540 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F;
	InChI InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37); Key:JSPCKALGNNVYOO-UHFFFAOYSA-N;

Zanzalintinib (also known as XL092) is an oral drug that is undergoing clinical studies. It could potentially be used to treat renal cell carcinoma (RCC). It is being developed by Exelixis.^[1]^[2]

STELLAR-303 is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in metastatic colorectal cancer.^[3]

STELLAR-304 (NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC).^[4]

^ Sharma MR, Subbiah V, Shapiro G, Pal SK, Agarwal N, Wentzel K, et al. (September 2022). "481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab". Annals of Oncology. 33: S760. doi:10.1016/j.annonc.2022.07.609. ISSN 0923-7534.
^ "Stellar 002". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.
^ "Stellar 303". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.
^ "Stellar 304". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.

[1] Sharma MR, Subbiah V, Shapiro G, Pal SK, Agarwal N, Wentzel K, et al. (September 2022). "481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab". Annals of Oncology. 33: S760. doi:10.1016/j.annonc.2022.07.609. ISSN 0923-7534.

[2] "Stellar 002". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.

[3] "Stellar 303". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.

[4] "Stellar 304". STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. Retrieved 2024-01-09.